FDA Approves Daratumumab Regimen for Transplant-Ineligible Myeloma
June 28th 2019The Food and Drug Administration approved daratumumab (Darzalex) plus lenalidomide and dexamethasone (Rd) for the treatment of patients with newly diagnosed myeloma who are not eligible for autologous stem cell transplant (ASCT), according to Janssen, the manufacturer of the drug.
FDA Approves Trastuzumab-Anns, a Herceptin Biosimilar
June 14th 2019The Food and Drug Administration (FDA) approved trastuzumab-anns (Kajinti), a biosimilar of trastuzumab (Herceptin) for the treatment of HER2-overexpressing breast cancer, metastatic gastric or gastroesophageal junction adenocarcinoma.
Low-Dose Drug Regimen Is Effective for Older, Frail Patients With Gastroesophageal Cancer
May 16th 2019A group of researchers in the UK sought out to determine the efficacy of a reduced-dose regimen of oxaliplatin (Eloxatin) and capecitabine (Xeloda) in this patient population through the randomized, phase III GO2 clinical trial.